atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$1.51 USD
-0.06 (-3.82%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.49 -0.02 (-1.32%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Brokerage Reports
atai Life Sciences N.V. [ATAI]
Reports for Purchase
Showing records 21 - 40 ( 64 total )
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
R&D Day Highlights Broad Pipeline Progress; Psychedelic Programs Advancing in Depression and Addiction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Management Meeting Takeaways; Multiple Potential Positive Events on Track For 4Q22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
JAMA Publication Further Supports Psychedelic Approach to Treat Alcoholism, a Potential $20B-Plus Global Market
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Leader in Emerging $400B Mental Healthcare Market With Multiple Near-Term Data Readouts Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Change Your Mind: Outlining Mental Healthcare Treatments of the Future With $400B Annual Revenue Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
Company: atai Life Sciences N.V.
Industry: Medical - Outpatient and Home Healthcare
1Q22 Results; Broad Pipeline Progress With Plethora of Potential Positive Events Expected Near-Term
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P